Your browser doesn't support javascript.
loading
Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma.
Qamra, Aditi; Xing, Manjie; Padmanabhan, Nisha; Kwok, Jeffrey Jun Ting; Zhang, Shenli; Xu, Chang; Leong, Yan Shan; Lee Lim, Ai Ping; Tang, Qianqao; Ooi, Wen Fong; Suling Lin, Joyce; Nandi, Tannistha; Yao, Xiaosai; Ong, Xuewen; Lee, Minghui; Tay, Su Ting; Keng, Angie Tan Lay; Gondo Santoso, Erna; Ng, Cedric Chuan Young; Ng, Alvin; Jusakul, Apinya; Smoot, Duane; Ashktorab, Hassan; Rha, Sun Young; Yeoh, Khay Guan; Peng Yong, Wei; Chow, Pierce K H; Chan, Weng Hoong; Ong, Hock Soo; Soo, Khee Chee; Kim, Kyoung-Mee; Wong, Wai Keong; Rozen, Steven G; Teh, Bin Tean; Kappei, Dennis; Lee, Jeeyun; Connolly, John; Tan, Patrick.
Afiliação
  • Qamra A; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore.
  • Xing M; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Padmanabhan N; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Kwok JJT; NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore.
  • Zhang S; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Xu C; Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore.
  • Leong YS; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Lee Lim AP; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Tang Q; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Ooi WF; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore.
  • Suling Lin J; Laboratory of Cancer Epigenome, Department of Medical Sciences, National Cancer Centre, Singapore.
  • Nandi T; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore.
  • Yao X; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore.
  • Ong X; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore.
  • Lee M; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore.
  • Tay ST; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Keng ATL; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Gondo Santoso E; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Ng CCY; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Ng A; Laboratory of Cancer Epigenome, Department of Medical Sciences, National Cancer Centre, Singapore.
  • Jusakul A; Laboratory of Cancer Epigenome, Department of Medical Sciences, National Cancer Centre, Singapore.
  • Smoot D; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Ashktorab H; NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore.
  • Rha SY; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
  • Yeoh KG; Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee.
  • Peng Yong W; Department of Medicine, Howard University, Washington, DC.
  • Chow PKH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Chan WH; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore.
  • Ong HS; Department of Gastroenterology & Hepatology, National University Hospital, Singapore.
  • Soo KC; Department of Haematology-Oncology, National University Hospital of Singapore, Singapore.
  • Kim KM; Department of General Surgery, Singapore General Hospital, Singapore.
  • Wong WK; Division of Surgical Oncology, National Cancer Centre Singapore, Singapore.
  • Rozen SG; Department of Upper Gastrointestinal & Bariatric Surgery, Singapore General Hospital, Singapore.
  • Teh BT; Department of Upper Gastrointestinal & Bariatric Surgery, Singapore General Hospital, Singapore.
  • Kappei D; Division of Surgical Oncology, National Cancer Centre Singapore, Singapore.
  • Lee J; Department of Pathology & Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Connolly J; Department of Upper Gastrointestinal & Bariatric Surgery, Singapore General Hospital, Singapore.
  • Tan P; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore.
Cancer Discov ; 7(6): 630-651, 2017 06.
Article em En | MEDLINE | ID: mdl-28320776
ABSTRACT
Promoter elements play important roles in isoform and cell type-specific expression. We surveyed the epigenomic promoter landscape of gastric adenocarcinoma, analyzing 110 chromatin profiles (H3K4me3, H3K4me1, H3K27ac) of primary gastric cancers, gastric cancer lines, and nonmalignant gastric tissues. We identified nearly 2,000 promoter alterations (somatic promoters), many deregulated in various epithelial malignancies and mapping frequently to alternative promoters within the same gene, generating potential pro-oncogenic isoforms (RASA3). Somatic promoter-associated N-terminal peptides displaying relative depletion in tumors exhibited high-affinity MHC binding predictions and elicited potent T-cell responses in vitro, suggesting a mechanism for reducing tumor antigenicity. In multiple patient cohorts, gastric cancers with high somatic promoter usage also displayed reduced T-cell cytolytic marker expression. Somatic promoters are enriched in PRC2 occupancy, display sensitivity to EZH2 therapeutic inhibition, and are associated with novel cancer-associated transcripts. By generating tumor-specific isoforms and decreasing tumor antigenicity, epigenomic promoter alterations may thus drive intrinsic tumorigenesis and also allow nascent cancers to evade host immunity.

Significance:

We apply epigenomic profiling to demarcate the promoter landscape of gastric cancer. Many tumor-specific promoters activate different promoters in the same gene, some generating pro-oncogenic isoforms. Tumor-specific promoters also reduce tumor antigenicity by causing relative depletion of immunogenic peptides, contributing to cancer immunoediting and allowing tumors to evade host immune attack. Cancer Discov; 7(6); 630-51. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 539.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Regiões Promotoras Genéticas Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Singapura

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Regiões Promotoras Genéticas Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Singapura